Skip to main content
CLOV
NASDAQ Finance

Clover Health Posts $6.4M Q3 Profit, Raises Full-Year 2026 Guidance Across All Metrics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Financial
Sentiment info
Positive
Importance info
8
Price
$4.67
Mkt Cap
$2.491B
52W Low
$1.58
52W High
$5.59
52W Position info
196% above low
Off High info
16% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

CLOV has more than doubled off its 52-week low of $1.58.

Summary

Clover Health reported $6.4M of Q3 2026 net income versus a $24.4M loss a year ago on 53% revenue growth, and raised full-year 2026 guidance across revenue, net income, gross profit and Adjusted EBITDA. It also named Clay Thornton permanent CFO.


Key Events · Earnings and Guidance · CLOV

  • Q3 Swing to $6.4M Profit

    Third quarter 2026 GAAP net income of $6.4M versus a $(24.4)M loss in Q3 2025, on total revenues of $759.3M, up 52.9% year-over-year.

  • Full-Year 2026 Guidance Raised

    Revenue guidance lifted to $2.97-3.00B from $2.92-3.00B, GAAP net income to $25-35M from $20-35M, gross profit to $540-555M from $525-555M, and Adjusted EBITDA to $75-85M from $70-85M.

  • Margins Improve on Membership Growth

    Insurance benefits expense ratio fell 240 bps to 91.1% while average Medicare Advantage membership rose 46.3% to 158,383; Adjusted EBITDA was $16.1M versus $2.1M a year ago.

  • CFO and CAO Made Permanent

    Clay Thornton, interim CFO since March 30, 2026, was appointed CFO effective November 4, 2026 at a $450,000 salary plus a $1.5M RSU grant; Joseph Oldakowski was named Chief Accounting Officer at $410,000 plus $850,000 in RSUs.


Analysis · CLOV · Finance

Clover turned a $24.4M year-ago loss into $6.4M of Q3 net income and lifted every full-year 2026 target, including GAAP net income to $25-35M — which would be its first profitable year. Revenue grew 53% to $759M while the benefits expense ratio improved 240 bps to 91.1%, showing the growth is coming with better margins rather than bought with underpricing. The 5-Star PPO rating covering ~98% of members underpins 2027 growth expectations. The main caveat is that the quarter's profit is thin relative to $759M of revenue, so the full-year number depends on Q4 holding up.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, CLOV was trading at $4.67 on NASDAQ in the Finance sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $1.58 to $5.59. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

CLOV - Latest Insights

CLOV
Nov 06, 2026, 8:03 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.45
Real-time Price: $3.71 info
Change: -$0.7402 (-17%) info
Market Cap: $1.976B info
CLOV
Nov 04, 2026, 4:06 PM EST
Source: Reuters
Importance Score:
8
Price at Filing: $4.71
Real-time Price: $3.71 info
Change: -$1.00 (-21%) info
Market Cap: $1.976B info
CLOV
Oct 08, 2026, 6:45 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $5.00
Real-time Price: $3.71 info
Change: -$1.29 (-26%) info
Market Cap: $1.976B info
CLOV
Aug 07, 2026, 8:04 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $4.69
Real-time Price: $3.71 info
Change: -$0.980 (-21%) info
Market Cap: $1.976B info
CLOV
Jul 17, 2026, 5:49 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $4.61
Real-time Price: $3.71 info
Change: -$0.900 (-20%) info
Market Cap: $1.976B info